Friday, 22 November 2013

Europace Publishes Data Supporting Use Of BRINAVESS™ (Vernakalant) As A First Line Agent For Pharmacological Cardioversion Of Atrial Fibrillation « New Drug Approvals

No comments:

Post a Comment